[go: up one dir, main page]

NO20081364L - Amorfe faste dispersjoner - Google Patents

Amorfe faste dispersjoner

Info

Publication number
NO20081364L
NO20081364L NO20081364A NO20081364A NO20081364L NO 20081364 L NO20081364 L NO 20081364L NO 20081364 A NO20081364 A NO 20081364A NO 20081364 A NO20081364 A NO 20081364A NO 20081364 L NO20081364 L NO 20081364L
Authority
NO
Norway
Prior art keywords
amorphous solid
solid dispersions
blindol
pyridazino
acetamide
Prior art date
Application number
NO20081364A
Other languages
English (en)
Inventor
Khawla Abdullah Abu-Izza
Irwin C Jacobs
John D Higgins
Micael Guillot
Nancy M Franson
William L Rocco
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37499538&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081364(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of NO20081364L publication Critical patent/NO20081364L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Det er beskrevet amorfe faste dispersjonsformuleringer omfattende 7-klor-N,N, 5trimetyl-4-okso-3-fenyl-3,5-dihydro-4H-pyridazino[4,5-blindol-l-acetamid.
NO20081364A 2005-08-29 2008-03-14 Amorfe faste dispersjoner NO20081364L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71215005P 2005-08-29 2005-08-29
PCT/US2006/033022 WO2007027494A2 (en) 2005-08-29 2006-08-24 Morphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino [4, 5-b] indole-1-acetamide

Publications (1)

Publication Number Publication Date
NO20081364L true NO20081364L (no) 2008-04-03

Family

ID=37499538

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081364A NO20081364L (no) 2005-08-29 2008-03-14 Amorfe faste dispersjoner

Country Status (30)

Country Link
US (1) US7713548B2 (no)
EP (1) EP1926476B1 (no)
JP (1) JP5026426B2 (no)
KR (1) KR20080061354A (no)
CN (1) CN101272767B (no)
AR (1) AR055615A1 (no)
AU (1) AU2006285111B8 (no)
BR (1) BRPI0615609A2 (no)
CA (1) CA2619438A1 (no)
CR (1) CR9750A (no)
DK (1) DK1926476T3 (no)
EA (1) EA015715B1 (no)
EC (1) ECSP088203A (no)
ES (1) ES2414434T3 (no)
HN (1) HN2008000360A (no)
HR (1) HRP20130533T1 (no)
IL (1) IL189587A (no)
MA (1) MA29783B1 (no)
ME (1) ME01560B (no)
NO (1) NO20081364L (no)
NZ (1) NZ566313A (no)
PL (1) PL1926476T3 (no)
PT (1) PT1926476E (no)
RS (1) RS52914B (no)
SI (1) SI1926476T1 (no)
TN (1) TNSN08069A1 (no)
TW (1) TWI398250B (no)
UA (1) UA93517C2 (no)
WO (1) WO2007027494A2 (no)
ZA (1) ZA200801893B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014KN02423A (no) 2006-04-07 2015-05-01 Vertex Pharma
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
EP2155166A2 (en) * 2007-05-11 2010-02-24 F. Hoffmann-Roche AG Pharmaceutical compositions for poorly soluble drugs
CN101959856A (zh) * 2008-03-11 2011-01-26 雷迪博士实验室有限公司 来那度胺的制备
JP2012500268A (ja) * 2008-08-18 2012-01-05 サノフィ−アベンティス・ユー・エス・エルエルシー ７−クロロ−Ｎ，Ｎ，５−トリメチル−４−オキソ−３−フェニル−３，５−ジヒドロ−４Ｈ−ピリダジノ［４，５−ｂ］インドール−１−アセトアミドの多形体を製造するための方法
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2804202T3 (es) * 2010-03-25 2021-02-04 Vertex Pharma Producto intermedio sintético de Formula cristalina de (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5il)-N-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2il)-1h-indol-5il)ciclopropanocarboxamida
IN2012DE00674A (no) 2012-03-07 2015-08-21 Nat Inst Of Pharmaceutical Education And Res Niper
KR101986683B1 (ko) 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
EP3039599A4 (en) * 2013-08-30 2017-04-19 Hewlett-Packard Enterprise Development LP Comparing real-time movements to pattern profile background
WO2015141662A1 (ja) 2014-03-18 2015-09-24 武田薬品工業株式会社 固体分散体
EP3424534B1 (en) 2014-04-15 2021-06-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
CN113925833A (zh) 2016-02-29 2022-01-14 豪夫迈·罗氏有限公司 包含酪氨酸蛋白激酶抑制剂的剂型组合物
CA3066046A1 (en) * 2017-07-04 2019-01-10 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition and method for preparing same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091381A (en) * 1991-04-12 1992-02-25 Biomeasure, Inc. 2H-1,3,4-benzotriazepin-2-ones
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
FR2766823B1 (fr) 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
ATE400251T1 (de) 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
EP1027887B1 (en) * 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
FR2829939B3 (fr) * 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
EA200800713A1 (ru) 2008-10-30
DK1926476T3 (da) 2013-07-01
PL1926476T3 (pl) 2013-08-30
TNSN08069A1 (en) 2009-07-14
AR055615A1 (es) 2007-08-29
IL189587A0 (en) 2008-08-07
ZA200801893B (en) 2009-08-26
PT1926476E (pt) 2013-07-10
CN101272767B (zh) 2012-08-29
NZ566313A (en) 2011-04-29
SI1926476T1 (sl) 2013-07-31
EA015715B1 (ru) 2011-10-31
AU2006285111B8 (en) 2012-05-17
BRPI0615609A2 (pt) 2011-05-24
AU2006285111A1 (en) 2007-03-08
ES2414434T3 (es) 2013-07-19
EP1926476A2 (en) 2008-06-04
HK1124785A1 (en) 2009-07-24
CA2619438A1 (en) 2007-03-08
EP1926476B1 (en) 2013-04-10
UA93517C2 (en) 2011-02-25
WO2007027494A3 (en) 2007-08-02
HN2008000360A (es) 2011-05-31
CN101272767A (zh) 2008-09-24
US20080160080A1 (en) 2008-07-03
HRP20130533T1 (en) 2013-07-31
WO2007027494A2 (en) 2007-03-08
IL189587A (en) 2012-12-31
JP5026426B2 (ja) 2012-09-12
JP2009506114A (ja) 2009-02-12
CR9750A (es) 2008-06-18
TW200727902A (en) 2007-08-01
ECSP088203A (es) 2008-06-30
MA29783B1 (fr) 2008-09-01
US7713548B2 (en) 2010-05-11
TWI398250B (zh) 2013-06-11
AU2006285111B2 (en) 2012-04-26
RS52914B (sr) 2014-02-28
ME01560B (me) 2014-04-20
KR20080061354A (ko) 2008-07-02

Similar Documents

Publication Publication Date Title
NO20081364L (no) Amorfe faste dispersjoner
UY3402Q (es) Diseno de tractor
WO2006042138A8 (en) Systems and methods for ex-vivo organ care
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
TW200732349A (en) Anti-OX40L antibodies and methods using same
BRPI0811046A2 (pt) Composto de hidrazida heterocíclica e uso pesticida do mesmo.
TW200737269A (en) Ion sources, systems and methods
TW200717389A (en) Luminance adjustment
WO2009042114A3 (en) Phenazine derivatives and uses thereof
MX2010002028A (es) Metodos y composiciones para modular celulas t.
WO2007120334A8 (en) Methods and compositions for targeting polyubiquitin
TW200715634A (en) Stable organic devices
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
TW200715969A (en) Fungicidal active-compound combination
GB2464417A (en) Security deterrent mark and methods of forming the same
BRPI0814989A8 (pt) Derivado de triazolilpiridina cetona, e herbicidas
MX2007005202A (es) Polisacaridos de estreptococo modificados y usos de los mismos.
MY143382A (en) Aqueous rodenticide formulations
MY139010A (en) 6-azo-5, 5'-dihydroxy -7,7'-disulfo-2-2'-dinaphthylamine derivatives
WO2007067729A3 (en) Microbial vaccine and vaccine vector
TW200724152A (en) Oligopeptide, derivative thereof, and pharmaceutical composition comprising the same
ATE434604T1 (de) Amorphes tamsulosin-hydrochlorid
CY1114124T1 (el) Αμορφες στερεες διασπορες της 7-χλωρο-ν,ν,5-τριμεθυλ-4-οξο-3-φαινυλ-3,5- διϋδρο-4η-πυριδαζινο[4,5-β]ινδολη-1-ακεταμιδης
Азімов et al. Êîðîòê³ â³äîìîñò³ Êîðîòê³ â³äîìîñò³ ïðî àâòîð³â ïðî àâòîð³â
HN2002000177A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application